The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress‐independent growth inhibition of pancreatic cancer cells through G2/M cell‐cycle arrest and apoptosis
Open accessAbstract
Cantharidin is an active constituent of mylabris, a traditional Chinese medicine. It is a potent and selective inhibitor of protein phosphatase 2A (PP2A) that plays an important role in control of cell cycle, apoptosis, and cell‐fate determination. Owing to its antitumor activity, cantharidin has been frequently used in clinical practice. In the present study, we investigated the therapeutic potential of cantharidin in pancreatic cancer. Cantharidin efficiently inhibited the growth of pancreatic cancer cells, but presented a much lighter toxicity effect against normal pancreatic duct cells. It caused G2/M cell‐cycle arrest that was accompanied by the down‐regulation of cyclin‐dependent kinase 1 (CDK1) and up‐regulation of p21 expression. It induced apoptosis and elevated the expressions of pro‐apoptotic factors tumor necrosis factor‐α (TNF‐α), TNF‐related apoptosis inducing receptor 1 (TRAILR1), TRAILR2, Bad, Bak, and Bid, and decreased the expression of anti‐apoptotic Bcl‐2. Activation of caspase‐8 and caspase‐9 suggested that both extrinsic and intrinsic pathways are involved in the induction of apoptosis. Interestingly, unlike previous studies on other cancer cells, we found that the inhibitory role of cantharidin is independent of oxidative stress in pancreatic cancer cells. Mitogen‐activated protein kinases (MAPKs), including ERK, JNK, and p38, were activated after treatment with cantharidin. Inhibition of JNK, but not ERK or p38, alleviated the cytotoxity effect of cantharidin, suggesting cantharidin exerted its anticancer effect through the JNK‐dependent way. Hence, in addition to being an attractive candidate compound with therapeutic potential, cantharidin also highlighted the possibility of using PP2A as a therapeutic target for pancreatic cancer treatment. (Cancer Sci 2010; 101: 1226–1233)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAPK signal pathways in the regulation of cell proliferation in mammalian cells
ZHANG, W., & LIU, H. T. (2002) · Cell Research · doi:10.1038/sj.cr.7290105 · Cited by 2,845
Oxidative stress and apoptosis: Impact on cancer therapy
Ozben, T. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20874 · Cited by 751
PP2A: the expected tumor suppressor
Janssens, V., Goris, J., & Van Hoof, C. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.004 · Cited by 426
Genetic profile of 22 pancreatic carcinoma cell lines: Analysis of K-ras, p53, p16 and DPC4/Smad4
Moore, P. S., Sipos, B., Orlandini, S., Sorio, C., Real, F. X., Lemoine, N. R., Gress, T., Bassi, C., Klöppel, G., Kalthoff, H., et al. (2001) · Virchows Archiv · doi:10.1007/s004280100474 · Cited by 329
Cited by
Terpenoids: natural products for cancer therapy
Huang, M., Lu, J.-J., Huang, M.-Q., Bao, J.-L., Chen, X.-P., & Wang, Y.-T. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.727395 · Cited by 333
Metadata
- Authors
- Li, W., Xie, L., Chen, Z., Zhu, Y., Sun, Y., Miao, Y., Xu, Z., & Han, X.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2010-04-19
- Volume
- 101
- Issue
- 5
- Pages
- 1226-1233
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2077536394
- Cited by
- 185
- References
- 4
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress‐independent growth inhibition of pancreatic cancer cells through G2/M cell‐cycle arrest and apoptosis. https://app.cochat.ai/papers/10.1111/j.1349-7006.2010.01523.x
- The paper
- Li, W., Xie, L., Chen, Z., Zhu, Y., Sun, Y., Miao, Y., Xu, Z., & Han, X. (2010). Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress‐independent growth inhibition of pancreatic cancer cells through G2/M cell‐cycle arrest and apoptosis. Cancer Science. https://doi.org/10.1111/j.1349-7006.2010.01523.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.